The negative inotropic effect of esmolol on isolated cardiac muscle

Scandinavian Cardiovascular Journal

Volumn 39, Issue 4, 2005, Pages 250-254

  Arlock, Per ^a   Wohlfart, B ^a   Sjoberg T ^a   Steen, S ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Action potential; Beta adrenergic blocker; Cardiac muscle; Contractility; Membrane currents; Myocytes; Voltage clamp

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; ESMOLOL; SHORT ACTING DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CURRENT; CONTROLLED STUDY; DOSE RESPONSE; GUINEA PIG; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; HYPOTENSION; INOTROPISM; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CALCIUM CHANNELS; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; GUINEA PIGS; MODELS, ANIMAL; MODELS, CARDIOVASCULAR; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PAPILLARY MUSCLES; PATCH-CLAMP TECHNIQUES; PROPANOLAMINES; SODIUM CHANNELS; STIMULATION, CHEMICAL; SWINE;

EID: 25444476096     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017430510035952     Document Type: Article

References (19)

1. Murthy VS, Frishman WH. Controlled beta-receptor blockade with esmolol and flestolol. Pharmacotherapy. 1988;8: 168-82.
2. Turlapaty P, Laddu A, Murthy VS, Singh B, Lee R. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings. Am Heart J. 1987;114:866-85.
3. Wolman RL, Fiedler MA. Esmolol and beta-adrenergic blockade. Aana J. 1991;59:541-8.
4. Benfield P, Sorkin EM. Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1987;33:392-412.
5. Angaran DM, Schultz NJ, Tschida VH. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent. Clin Pharm. 1986;5:288-303.
6. Wiest D. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet. 1995; 28:190-202.
7. 2+ following extrasystoles in guinea-pig trabeculae microinjected with fluo-3-a comparison with frog skeletal muscle fibres. Acta Physiol Scand. 2000;169:1-11.
8. Roscher R, Arlock P, Sjöberg T, Steen S. Effects of dopamine on porcine myocardial action potentials and contractions at 37°C and 32°C. Acta anaesthesiologica Scandinavica. 2001; 45:421-6.
9. Arlock P, Wohlfart B, Sjöberg T, Steen S. Disastrous physiological effects of saline on the cell membrane demonstrated in cardiac cells. Scand Cardiovasc J. 2004;38:300-6.
10. Wettwer E, Scholtysik G, Schaad A, Himmel H, Ravens U. Effects of the new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters. J Cardiovasc Pharmacol. 1991;17:480-7.
11. Stankovicova T, Szilard M, De Scheerder I, Sipido KR. M cells and transmural heterogeneity of action potential configuration in myocytes from the left ventricular wall of the pig heart. Cardiovasc Res. 2000;45:952-60.
12. Himmel HM, Amos GJ, Wettwer E, Ravens U. Effects of the calcium sensitizer [+]-EMD 60263 and its enantiomer [-]-EMD 60264 on cardiac ionic currents of guinea pig and rat ventricular myocytes. J Cardiovasc Pharmacol. 1999;33:301-8.
13. Boyett MR, Moore M, Jewell BR, Montgomery RA, Kirby MS, Orchard CH. An improved apparatus for the optical recording of contraction of single heart cells. Pflugers Arch. 1988;413:197-205.
14. Muraki K, Nakagawa H, Nagano N, Henmi S, Kawasumi H, Nakanishi T, et al. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle. J Pharmacol Exp Ther. 1996;278:555-63.
15. Gorczynski RJ, Shaffer JE, Lee RJ. Pharmacology of ASL-8052, a novel beta-adrenergic receptor antagonist with an ultrashort duration of action. J Cardiovasc Pharmacol. 1983; 5:668-77.
16. Blanski L, Lutz J, Laddu A. Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients. Heart Lung. 1988;17:80-9.
17. Gray RJ. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker. Chest. 1988;93: 398-403.
18. Barbier GH, Shettigar UR, Appunn DO. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol. Int J Clin Pharmacol Ther. 1995;33:212-8.
19. Bessho R, Chambers DJ. Myocardial protection: the efficacy of an ultra-short-acting beta-blocker, esmolol, as a cardioplegic agent. J Thorac Cardiovasc Surg. 2001;122:993-1003.